Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials - PubMed (original) (raw)
Randomized Controlled Trial
. 2006 May 1;24(13):2028-37.
doi: 10.1200/JCO.2005.04.3273.
Affiliations
- PMID: 16648502
- DOI: 10.1200/JCO.2005.04.3273
Randomized Controlled Trial
Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials
Irene L Wapnir et al. J Clin Oncol. 2006.
Abstract
Purpose: Locoregional failure after breast-conserving surgery is associated with increased risk of distant disease and death. The magnitude of this risk in patients receiving chemotherapy has not been adequately characterized.
Patients and methods: Our study population included 2,669 women randomly assigned onto five National Surgical Adjuvant Breast and Bowel Project node-positive protocols (B-15, B-16, B-18, B-22, and B-25), who were treated with lumpectomy, whole-breast irradiation, and adjuvant systemic therapy. Cumulative incidences of ipsilateral breast tumor recurrence (IBTR) and other locoregional recurrence (oLRR) were calculated. Kaplan-Meier curves were used to estimate distant-disease-free survival (DDFS) and overall survival (OS) after IBTR or oLRR. Cox models were used to model survival using clinical and pathologic factors jointly with IBTR or oLRR as time-varying predictors.
Results: Four hundred twenty-four patients (15.9%) experienced locoregional failure; 259 (9.7%) experienced IBTR, and 165 (6.2%) experienced oLRR. The 10-year cumulative incidence of IBTR and oLRR was 8.7% and 6.0%, respectively. Most locoregional failures occurred within 5 years (62.2% for IBTR and 80.6% for oLRR). Age, tumor size, and estrogen receptor status were significantly associated with IBTR. Nodal status and estrogen and progesterone receptor status were significantly associated with oLRR. The 5-year DDFS rates after IBTR and oLRR were 51.4% and 18.8%, respectively. The 5-year OS rates after IBTR and oLRR were 59.9% and 24.1%, respectively. Hazard ratios for mortality associated with IBTR and oLRR were 2.58 (95% CI, 2.11 to 3.15) and 5.85 (95% CI, 4.80 to 7.13), respectively.
Conclusion: Node-positive breast cancer patients who developed IBTR or oLRR had significantly poorer prognoses than patients who did not experience these events.
Similar articles
- Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer.
Anderson SJ, Wapnir I, Dignam JJ, Fisher B, Mamounas EP, Jeong JH, Geyer CE Jr, Wickerham DL, Costantino JP, Wolmark N. Anderson SJ, et al. J Clin Oncol. 2009 May 20;27(15):2466-73. doi: 10.1200/JCO.2008.19.8424. Epub 2009 Apr 6. J Clin Oncol. 2009. PMID: 19349544 Free PMC article. Clinical Trial. - Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases.
Komoike Y, Akiyama F, Iino Y, Ikeda T, Akashi-Tanaka S, Ohsumi S, Kusama M, Sano M, Shin E, Suemasu K, Sonoo H, Taguchi T, Nishi T, Nishimura R, Haga S, Mise K, Kinoshita T, Murakami S, Yoshimoto M, Tsukuma H, Inaji H. Komoike Y, et al. Cancer. 2006 Jan 1;106(1):35-41. doi: 10.1002/cncr.21551. Cancer. 2006. PMID: 16333848 - Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy.
Meric F, Mirza NQ, Vlastos G, Buchholz TA, Kuerer HM, Babiera GV, Singletary SE, Ross MI, Ames FC, Feig BW, Krishnamurthy S, Perkins GH, McNeese MD, Strom EA, Valero V, Hunt KK. Meric F, et al. Cancer. 2003 Feb 15;97(4):926-33. doi: 10.1002/cncr.11222. Cancer. 2003. PMID: 12569592 - Breast tumor recurrence following lumpectomy with and without breast irradiation: an overview of recent NSABP findings.
Fisher B, Wickerham DL, Deutsch M, Anderson S, Redmond C, Fisher ER. Fisher B, et al. Semin Surg Oncol. 1992 May-Jun;8(3):153-60. Semin Surg Oncol. 1992. PMID: 1496226 Review. - Lumpectomy for breast cancer: an update of the NSABP experience. National Surgical Adjuvant Breast and Bowel Project.
Fisher B, Redmond C. Fisher B, et al. J Natl Cancer Inst Monogr. 1992;(11):7-13. J Natl Cancer Inst Monogr. 1992. PMID: 1627432 Review.
Cited by
- Economic Evaluation of Population-Based BRCA1 and BRCA2 Testing in Canada.
Sun L, Wei X, Fierheller CT, Dawson L, Oxley S, Kalra A, Sia J, Feldman F, Peacock S, Schrader KA, Legood R, Kwon JS, Manchanda R. Sun L, et al. JAMA Netw Open. 2024 Sep 3;7(9):e2432725. doi: 10.1001/jamanetworkopen.2024.32725. JAMA Netw Open. 2024. PMID: 39264630 Free PMC article. - Cost-effectiveness of early vs delayed use of abemaciclib combination therapy for patients with high-risk hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer.
Chang SH, Svensson M, Hsin-Min Wang G, Wang Y, Kang HR, Park H. Chang SH, et al. J Manag Care Spec Pharm. 2024 Sep;30(9):942-953. doi: 10.18553/jmcp.2024.30.9.942. J Manag Care Spec Pharm. 2024. PMID: 39213142 Free PMC article. - A bibliometric worldview of breast-conserving surgery for breast cancer from 2013 to 2023.
Cao S, Wei Y, Huang J, Yue Y, Deng A, Zeng H, Wei W. Cao S, et al. Front Oncol. 2024 Jul 19;14:1405351. doi: 10.3389/fonc.2024.1405351. eCollection 2024. Front Oncol. 2024. PMID: 39099692 Free PMC article. - Post-Operative Radiation in Early Breast Cancer with N1 Disease: 10-Year Follow-Up.
Tang ELS, Sim EJ, Ang WW, Su J, Chen JJC, Chan MYP, Choo BA, Tan EY. Tang ELS, et al. Diseases. 2024 Jul 5;12(7):145. doi: 10.3390/diseases12070145. Diseases. 2024. PMID: 39057116 Free PMC article. - Surveillance Strategies After Primary Treatment for Patients with Invasive Lobular Carcinoma of the Breast: Method of Local Recurrence Detection After Breast-Conserving Surgery.
Clelland EN, Quirarte A, Rothschild HT, Kaur M, Mujir F, Record H, Wong JM, Mukhtar RA. Clelland EN, et al. Ann Surg Oncol. 2024 Oct;31(11):7315-7322. doi: 10.1245/s10434-024-15710-1. Epub 2024 Jul 2. Ann Surg Oncol. 2024. PMID: 38954091 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials